In a new, small study, transfusions of genetically altered cells called CAR-T cells were found to drive lupus disease into remission. T-cells are part of the immune system. In this therapy, scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them to create CAR-T cells.
Researchers infused CAR-T cells into five people with lupus (four women and one man). After infusion, the study participants saw a sharp drop in B cells (the cells responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases) and improved lupus disease symptoms. After three months of treatment, all five of the participants achieved remission.
Initial results from the study suggest that CAR-T cell therapy may be effective in treating lupus. More research is needed to further assess the therapy’s ability to eliminate autoimmunity and inflammation in people with lupus. Continue to follow the Lupus Foundation of America for updates on this potential breakthrough therapy for lupus. Learn more about treatments being studied for lupus.
Lupus Foundation of America, Texas Gulf Coast Chapter
440 Louisiana St Ste 900C
Houston, Texas 77002
713-529-0126
Fax: 713-529-0780
info@LupusTexas.org
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more